PDT Partners LLC Sells 14,555 Shares of Moderna, Inc. (NASDAQ:MRNA)

PDT Partners LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 68.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,745 shares of the company's stock after selling 14,555 shares during the period. PDT Partners LLC's holdings in Moderna were worth $280,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of MRNA. Allworth Financial LP increased its stake in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after buying an additional 281 shares during the period. Howard Capital Management Inc. boosted its holdings in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Moderna by 0.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Moderna by 39.1% during the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after buying an additional 356 shares during the period. Finally, New Insight Wealth Advisors raised its stake in Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after buying an additional 358 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

Shares of MRNA traded up $0.23 during mid-day trading on Monday, hitting $27.84. 7,799,065 shares of the company traded hands, compared to its average volume of 7,425,602. The stock has a market cap of $10.76 billion, a price-to-earnings ratio of -3.00 and a beta of 1.99. The stock has a 50-day moving average price of $29.52 and a two-hundred day moving average price of $37.34. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue for the quarter was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.07) earnings per share. On average, analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Royal Bank of Canada decreased their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Barclays dropped their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday. Finally, The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and decreased their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $53.95.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.